Last updated on May 2017

Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Schizophrenia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Adult patients (age ≥ 18 years at the time of aripiprazole once-monthly initiation)
    Male or female
    Diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental
    Disorders, Fifth edition (DSM-5), available at start of aripiprazole once-monthly
    treatment, and confirmed by the current investigator
    Aripiprazole once-monthly initiation (at least 1 injection) according to the clinical
    practice, at least 6 months before the inclusion and on June 1st 2015 or at a later
    date (index date)
    Aripiprazole once-monthly was the main antipsychotic at the time of treatment
    initiation
    Willingness to participate in the study; subjects must give their written consent to
    participate

You may not be eligible for this study if the following are true:

  • The patient has a psychiatric disorder other than schizophrenia as primary diagnosis
    Participation in a clinical trial during the retrospective follow-up period.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.